Related Experiment Video

Updated: Jun 20, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Effects of angiotensin II receptor blockers on dementia

Masaki Mogi1, Masatsugu Horiuchi

  • 1Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Ehime, Japan. mmogi@m.ehime-u.ac.jp

Hypertension Research : Official Journal of the Japanese Society of Hypertension
|September 4, 2009
PubMed

Insights

Angiotensin II receptor blockers (ARBs) show promise in preventing cognitive decline and dementia, particularly Alzheimer disease. Further research is needed to confirm their neuroprotective effects and therapeutic potential in elderly populations.

Area of Science:

  • Neuroscience
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • The renin-angiotensin system (RAS) plays a role in hypertension and target organ damage.
  • Angiotensin II receptor blockers (ARBs) are known to prevent stroke but their effect on dementia is unclear.
  • Emerging evidence suggests ARBs may offer neuroprotection against ischemic brain damage and cognitive impairment.

Purpose of the Study:

  • To review the effects of ARBs on the brain, focusing on dementia.
  • To explore the potential of ARBs in preventing cognitive impairment and neurodegenerative diseases.
  • To discuss future therapeutic strategies using ARBs for elderly individuals with cognitive disabilities.

Main Methods:

  • Review of preliminary experimental data on ARBs and brain function.
  • Analysis of recent reports on ARBs, amyloid beta deposition, and Alzheimer disease models.
  • Examination of cohort studies investigating ARB use and Alzheimer disease incidence.

Main Results:

  • ARBs may prevent ischemic brain damage and cognitive impairment.
  • Some ARBs have demonstrated the ability to reduce amyloid beta deposition in Alzheimer disease models.
  • Cohort studies suggest a lower incidence of Alzheimer disease in elderly patients treated with ARBs.

Conclusions:

  • ARBs show a beneficial role in cognitive impairment linked to vascular disease, Alzheimer disease, metabolic syndrome, and other neurodegenerative conditions.
  • ARBs represent a potential therapeutic approach for preventing and treating dementia.
  • Further investigation into ARBs' neuroprotective mechanisms and clinical efficacy is warranted for elderly populations.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...